Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Review which Dividend Aristocrats ETF has the highest management fee and how it affects net performance.
28,021 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
stifel just predicted bitcoin could fall toward $38,000, a chart-based call rooted in 15-year crash bottoms that has ...
NVIDIA and Alphabet reveal divergent AI strategies, highlighting hardware rails versus cloud-powered services, and si...
A surge of mega IPOs in 2026 is minting new fortunes. Melinda French Gates’ advice for these newcomers centers on gen...
Steak ’n Shake reports a 16% July lift in U.S. same-store sales and attributes it to Bitcoin adoption, but the absenc...
A confidential settlement in Maryland ends a high-profile dispute over HeLa cell patents and profits, signaling a new...
Pinterest stock is slipping mid-session, dropping around 6% to near $18.75 as peers like Meta and Snap show lighter d...
Shiba Inu’s key on-chain metric has dropped to a five-year low, signaling caution but also a possible setup for a fut...
A Detroit autoworker’s dream of winning margins meets a global market that’s increasingly dependent on China. This ar...
Five years into Andy Jassy’s tenure, a $10,000 investment in Amazon would be worth about $13,500, a gain that trails ...
Standard Chartered trims its XRP outlook to $2.80, a 65% drop that marks the sharpest forecast revision among its cry...
A hypothetical scenario finds that a 40% cut in S&P 500 employment could erase roughly 12 million jobs, with broad im...